Drug Discovery World

MAY 1, 2024

Jonathan Kwok, CEO and Co-founder of Infinitopes, said: “Our therapies are emerging at a time when blockbuster checkpoint inhibitors are hitting their peak, capable of preventing tumour recurrence in 30-40% of patients at best. Diana Spencer, Senior Digital Content Editor, DDW The post Cancer vaccine developer secures £12.8m

Vaccine 147

Vaccine Clinical Trials Research Science 147

Drug Discovery World

SEPTEMBER 18, 2023

Jonathan Riess, lead investigator of the trial at the UC Davis Comprehensive Cancer Center, presented encouraging early clinical and biomarker data supporting the combination treatment for patients with metastatic non-small cell lung cancer (NSCLC). These data were presented at the IASLC 2023 World Conference on Lung Cancer (WCLC).

Vaccine 130

Vaccine Trials Therapies Treatment 130

Drug Discovery World

DECEMBER 18, 2023

An effective HIV vaccine may need to prompt strong responses from CD8+ T cells to protect people from acquiring HIV, according to a study from the National Institute of Allergy and Infectious Diseases (NIAID). Further tests revealed that this dampened response was due to reduced sensitivity to HIV of vaccine recipients’ T-cell receptors.

Vaccine 147

Vaccine Clinical Trials Laboratories Virus 147

Drug Discovery World

MARCH 27, 2023

The first subjects have been dosed in a Phase I clinical trial of VXX-401, an investigational vaccine designed to lower low-density lipoprotein (LDL) cholesterol, a known factor in heart disease. We’re excited to get this first-in-human trial of VXX-401 started.

Vaccine 130

Vaccine Immune Response Trials Clinical Trials 130

Drug Discovery World

OCTOBER 27, 2023

HB-400, a novel arenaviral therapeutic vaccine developed by HOOKIPA Pharma and Gilead Sciences, has been shown to generate robust T cell responses specific to hepatitis B virus with high antibody levels in a preclinical setting. A Phase I clinical trial to evaluate the safety and tolerability of HB‑400 in humans is ongoing.

Vaccine 130

Vaccine Immune Response Virus Clinical Trials 130

Advarra

JANUARY 11, 2024

The applications of mRNA-based therapies in cancer research represent one of the next groundbreaking steps toward improved cancer treatments. While mRNA usage has played several roles in clinical research , oncology researchers in particular are eager to explore the possibilities of mRNA-based cancer vaccines.

Vaccine 52

Vaccine Therapies Clinical Trials Small Molecule 52

Drug Discovery World

APRIL 16, 2023

Personalised mRNA-based cancer vaccine mRNA-4157/V940, in combination with the immune checkpoint inhibitor pembrolizumab (Keytruda) improved recurrence-free survival (RFS) compared with pembrolizumab alone in patients with high-risk melanoma. According to the results of the primary trial analysis, after 18 months, the RFS was 78.6%

Vaccine 130

Vaccine Immune Response Medical Schools Trials 130

Drug Discovery World

JUNE 6, 2024

With the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting , taking place from 30 May to 3 June, the drug discovery announcements have been coming thick and fast, with many new cancer therapies making significant strides forward in our ability to treat the disease.

Drug Research 195

Drug Research Research Vaccine Clinical Trials 195

Drug Discovery World

JULY 27, 2023

The Phase I study was a first-in-human trial to investigate safety, immunogenicity, and survival in patients with advanced NSCLC (defined as metastatic or locally advanced disease) when administered the allogeneic dendritic cell (DC) vaccine VAC2.

Vaccine 130

Vaccine Clinical Trials Engineering Disease 130

Drug Discovery World

NOVEMBER 8, 2022

Merck has exercised its option to jointly develop and commercialise personalised cancer vaccine (PCV) mRNA-4157/V940 pursuant to the terms of its existing collaboration and license agreement with Moderna. . KEYNOTE-942 is an ongoing randomised, open-label Phase II trial that enrolled 157 patients with high-risk melanoma.

Vaccine 130

Vaccine Immune Response Research Laboratories Clinical Trials 130

Drug Discovery World

MAY 17, 2024

From a weight loss drug that prevents heart attacks and a gene therapy that restores hearing, to a vaccine that can treat viruses that don’t exist yet, our chosen news stories this week all represent potential breakthroughs in their respective fields.

Therapies 130

Therapies Vaccine RNA Clinical Trials 130

Drug Discovery World

APRIL 26, 2024

The leading news story this week has been the launch of a new clinical trial in the UK for a melanoma personalised mRNA cancer vaccine, but there have been a number of other interesting developments in cancer drug discovery. The post This week in drug discovery (22-26 April) appeared first on Drug Discovery World (DDW).

Clinical Trials 130

Clinical Trials Vaccine Drugs Trials 130

Drug Discovery World

OCTOBER 27, 2023

My news highlights this week feature a variety of treatment approaches, from cell therapy and antibody-drug conjugate to autotaxin inhibitor and arenaviral vaccine, all entering early in-human clinical trials to treat a range of diseases.

Vaccine 130

Vaccine Drugs Therapies Clinical Trials 130

Drug Discovery World

SEPTEMBER 22, 2023

As we approach another autumn/winter season in the northern hemisphere, Covid-19 vaccines are once again making the headlines, but in the last week we have also reported on vaccine trials for a number of other conditions, including Nipah virus, rabies and lung cancer.

Vaccine 130

Vaccine Clinical Trials Virus Drugs 130

Drug Discovery World

APRIL 14, 2023

Clinical trials are, undoubtedly, an essential part of the drug development process, providing us with valuable information about the safety and efficacy of new treatments and therapies. of participants 2 Covid-19 vaccination trials. In fact, these demographics which make up 13.8%

Clinical Trials 130

Clinical Trials Trials Pharmaceuticals Vaccine 130

Drug Discovery World

APRIL 19, 2024

The headline news this week all concerns clinical trials for new drugs that could have a significant impact on future patient treatment, including trials testing therapeutics for ALS, cystic fibrosis, gonorrhoea, TB and Parkinson’s. The post This week in drug discovery (15-19 April) appeared first on Drug Discovery World (DDW).

Clinical Trials 130

Clinical Trials Vaccine Trials Drugs 130

Drug Discovery World

SEPTEMBER 6, 2022

DDW Editor Reece Armstrong looks at the cell and gene therapy landscape, examining the challenges facing developers and the trends we can expect to see throughout the year. . There’s no doubt that cell and gene therapies present some of the most exciting opportunities for emerging drugs. billion, compared to $19.9 Cancer is king .

Therapies 130

Therapies Clinical Trials Vaccine Disease 130

Drug Discovery World

JULY 26, 2024

Perhaps most note-worthy, shingles vaccines Shingrix has been shown to reduce the risk of dementia by 17%, and TikoMed’s ALS drug caused a long-term slowing of ALS progression in a Phase II trial. There have been some interesting developments in neuroscience this week.

Vaccine 130

Vaccine Drugs Disease Therapies 130

Drug Discovery World

FEBRUARY 24, 2023

AELIX Therapeutics has announced positive results from its randomised, placebo-controlled Phase IIa therapeutic HIV vaccine and immune modulator combination clinical trial. The trial also evaluated the efficacy of HTI vaccines in combination with VES to avoid, delay or contain viral rebound compared to a placebo group.

Immune Response 130

Immune Response Vaccine Trials Clinical Trials 130

Drug Discovery World

APRIL 29, 2024

The leading news story this week has been the launch of a new clinical trial in the UK for a melanoma personalised mRNA cancer vaccine, but there have been a number of other interesting developments in cancer drug discovery.

Clinical Trials 130

Clinical Trials Vaccine Trials Treatment 130

Drug Discovery World

JANUARY 9, 2023

It is hoped that a new partnership between the UK government and BioNTech will help accelerate clinical trials of personalised immunotherapies for cancer and infectious disease vaccines. . The agreement means cancer patients will get early access to trials exploring personalised mRNA therapies, like cancer vaccines. .

Research 130

Research Vaccine Government Clinical Trials 130

Drug Target Review

FEBRUARY 21, 2024

Stem cell transplants have saved patients’ lives time and time again, which led us to launch our own Stem Cell Transplant and Cellular Therapy Program. Regarding CAR-T cell therapy, could you highlight the promising findings that have been identified in the early stages of drug discovery, as well as potential challenges?

Therapies 64

Therapies Treatment FDA Approval Vaccine 64

Drug Discovery World

OCTOBER 30, 2023

The news highlights this week feature a variety of treatment approaches, from cell therapy and antibody-drug conjugate to autotaxin inhibitor and arenaviral vaccine, all entering early in-human clinical trials to treat a range of diseases.

Clinical Trials 130

Clinical Trials Vaccine Therapies Trials 130

Drug Discovery World

JULY 8, 2024

Syncromune’s SYNC-T SV-102 therapy is a personalised treatment that comprises of an in situ vaccine via partial oncolysis of a tumour followed by intratumoral infusion of the SV-102 fixed-dose multi-target biologic drug into the lysed tumour.

FDA 147

FDA Treatment Therapies Vaccine 147

Vial

DECEMBER 11, 2023

In the decades since its identification in 1989, advances in clinical research for new Hepatitis C therapies and the introduction of direct-acting antiviral agents (DAAs) have led to viral eradication in more than 98% of patients, resulting in HCV crossing from manageable to being the first curable , chronic viral infection.

Clinical Research 52

Clinical Research Therapies Research Vaccine 52

Drug Discovery World

APRIL 3, 2024

In the last few years, immunotherapies like immune checkpoint inhibitors, vaccines and cell and gene therapies have revolutionised the treatment of cancer, and targeted drugs like monoclonal antibodies (mAbs), poly-ADP ribose polymerase (PARP) inhibitors and targeted protein degraders are also playing an important role.

Targeted Protein Degradation 130

Targeted Protein Degradation Research Therapies Drugs 130

Drug Discovery World

APRIL 21, 2023

The event showcased the very latest innovations in cancer therapies, from personalised mRNA vaccines to bispecific antibodies. This is according to results of a Phase I/II clinical trial presented at the AACR Annual Meeting 2023 in Florida. overall response rate.

Clinical Trials 130

Clinical Trials Vaccine Drugs Therapies 130

Drug Discovery World

AUGUST 1, 2024

DDW Editor Reece Armstrong speaks to Dr Steven Powell , co-founder of Glen Clova Scientific (GCS), about the company’s approach of using virus-like particles (VLPs) to treat conditions such as eczema and asthma, and what the current market looks like for this therapy area. Ultimately, however, clinical trials are needed to confirm efficacy.

Clinical Trials 147

Clinical Trials Drugs Therapies Production 147

Drug Discovery World

SEPTEMBER 14, 2023

Evaluating Immatics’ IMA203 TCR-T therapy, targeting PRAME, in combination with Moderna’s PRAME mRNA-based cancer vaccine. Evaluating Immatics’ IMA203 TCR-T therapy, targeting PRAME, in combination with Moderna’s PRAME mRNA-based cancer vaccine.

Vaccine 130

Vaccine Bioinformatics Clinical Trials Therapies 130

Drug Discovery World

SEPTEMBER 15, 2023

Phase I trial of next-generation srRNA rabies vaccine Replicate Bioscience has dosed the first participant in a Phase I trial of its RBI-4000 vaccine for the prevention of rabies.

Pharma Companies 130

Pharma Companies Drugs RNA Vaccine 130

Drug Discovery World

APRIL 29, 2024

The leading news story this week has been the launch of a new clinical trial in the UK for a melanoma personalised mRNA cancer vaccine, but there have been a number of other interesting developments in cancer drug discovery.

Clinical Trials 130

Clinical Trials Vaccine Treatment Therapies 130

Drug Discovery World

JULY 10, 2023

If there’s one thing I would take from the Summer 2023 issue of Drug Discovery World , it would be that the application of technologies and processes throughout the pharmaceutical industry are changing how scientists pursue the development of therapies. Disappointing, but work is continuing.

Pharmaceuticals 130

Pharmaceuticals Therapies Vaccine Clinical Trials 130

Drug Discovery World

JUNE 16, 2023

The top stories: FDA approves Phase III cerebral Adrenoleukodystrophy trial THE FDA has approved Minoryx Therapeutics’ Phase III clinical trial (CALYX) of leriglitazone, to treat adult male X-linked Adrenoleukodystrophy (X-ALD) patients with cerebral Adrenoleukodystrophy (cALD).

FDA Approval 130

FDA Approval Clinical Trials FDA Drugs 130

Drug Discovery World

MAY 23, 2024

A team of scientists in the US and the UK are combining a genetically modified cold sore virus with a cancer vaccine to treat an aggressive type of brain cancer in children. The research team has already used the virus in a small Phase I trial where responses to the treatment were seen in 11 out of 12 children.

Virus 147

Virus Immune Response Vaccine Engineering 147

The Pharma Data

SEPTEMBER 23, 2020

The halting of AstraZeneca’s COVID-19 vaccine trial around the world was cause for much initial concern over the eventual safety and efficacy of the therapy. Trials have resumed in the UK, Brazil and South Africa, but US trials remain on hold. Matt Fellows. Source link.

Vaccine 52

Vaccine Trials Science Regulations 52

The Pharma Data

SEPTEMBER 12, 2020

Food and Drug Administration to expand the enrollment of their Phase 3 pivotal COVID-19 vaccine trial to up to approximately 44,000 participants which also allows for the enrollment of new populations. The pivotal trial is event-based and there are many variables that will ultimately impact read-out timing.

Vaccine 52

Vaccine Trials Clinical Trials Small Molecule 52

Drug Discovery World

MARCH 31, 2023

News round-up for 27-31 March by DDW Digital Content Editor Diana Spencer. As March draws to a close, this week’s key announcements have demonstrated the breadth of international approaches to tackling cancer, with vaccines, proenzymes, immunotherapies and antibody-based treatments all currently under investigation around the world.

Vaccine 130

Vaccine Drugs Clinical Trials International 130